title: Effect of arbekacin on a methicillin-resistant Staphylococcus aureus-induced biofilm in a rat model.
abstract: Biofilms are a major concern for clinicians in the treatment of infectious disease because of their resistance to a wide range of antibiotics. Arbekacin, an aminoglycoside antibiotic, is the drug of choice for the treatment of infection caused by methicillin-resistant Staphylococcus aureus (MRSA). However, it has not yet been defined whether arbekacin tends to penetrate into the biofilm structure induced by MRSA infection. In this study, we treated a biofilm mode of MRSA growth with arbekacin, using a rat air-pouch model. The model has the advantage of permitting frequent sampling of exudates for bacterial counts and antibacterial activity. A clear dose-dependent bactericidal effect was detected in rats treated with arbekacin at concentrations between 0.3 and 10 mg/kg, but 0.1 mg/kg of arbekacin was ineffective against the experimental MRSA infection in rats. Morphological studies using scanning electron microscopy and histochemical staining demonstrated that an effective dosage of arbekacin induced dramatic changes in the biofilm membranous structure as well as in the inflammatory response, resulting in eradication of the biofilm structure and resolution of inflammation.
authors.affiliation: Division of Clinical Nutrition, Department of Nutrition, Sagami Women's University, 2-1-1 Bunkyo, Sagamihara, Kanagawa, 228-8533, Japan.
authors.forename: Yuka
authors.initials: Y
authors.lastname: Yoshikawa
authors.forename: Keiko
authors.initials: K
authors.lastname: Morikawa
authors.forename: Mitsuko
authors.initials: M
authors.lastname: Nonaka
authors.forename: Ikuko
authors.initials: I
authors.lastname: Torii
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development; D003982:Dibekacin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D006099:Granuloma / Q000188:drug therapy; D006801:Humans; D008297:Male; D016106:Methicillin Resistance; D008855:Microscopy, Electron, Scanning; D009336:Necrosis; D051381:Rats; D017208:Rats, Wistar; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development / Q000648:ultrastructure; D016896:Treatment Outcome
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003982:Dibekacin; C031986:arbekacin